Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (NCT03761108)
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer
Who can join: Review the eligibility criteria below.
Location: Sylvester Comprehensive Cancer Center — Miami, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Moffitt Cancer Center - McKinley Drive — Tampa, Florida
- Emory University Hospital — Atlanta, Georgia
- Indiana University_Michigan Street — Indianapolis, Indiana
- Norton Cancer Institute — Louisville, Kentucky
- C. S. Mott_University of Michigan — Ann Arbor, Michigan
- Barbara Ann Karmanos Cancer Center — Detroit, Michigan
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University Medical Center — New York, New York
- Ohio State University James Cancer Hospital — Columbus, Ohio
- Oregon Health and Science University (OHSU) Marquam Hill Campus — Portland, Oregon
- University of Texas MD Anderson Clinic — Houston, Texas
- Swedish Cancer Institute — Seattle, Washington
- ZNA Psychiatrisch Ziekenhuis Stuivenberg — Antwerp,
- Cliniques Universitaires Saint-Luc — Brussels,
- Universitatsklinikum Essen — Essen, North Rhine-Westphalia
- Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR — Mainz, Rhineland-Palatinate
- Universitatsklinikum Wurzburg — Würzburg,
- Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital — Nagoya, Aichi-ken
- Nagoya City University Hospital — Nagoya, Aichi-ken
- National Cancer Center Hospital East — Kashiwa-shi, Chiba
- Gunma University Hospital — Maebashi, Gunma
- Ibaraki Prefectural Central Hospital — Kasama-shi, Ibaraki
- University Hospital Kyoto Prefectural Univ of Medicine — Kyoto, Kyoto
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.